Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Avenue Therapeutics

NASDAQ ATXI
$4.00 -0.15 -3.75%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 18 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

102.39M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
100.61M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.68
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
25.60M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
2,384.47 %

Upcoming events Avenue Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Avenue Therapeutics

Stock analysis Avenue Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-8.86 8.79
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
64.72 25.38
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
- 4.40
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
- 0.50
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-730.09 9.54

Price change Avenue Therapeutics per year

1.27$ 7.69$
Min Max

Summary analysis Avenue Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Avenue Therapeutics

Revenue and net income Avenue Therapeutics

All parameters

Stock news Avenue Therapeutics

All news
5 January в 17:50

Avenue Therapeutics Shares Drop 29% After Warrants Exercised

5 January в 17:45

Avenue Therapeutics Shares Drop 29% After Warrants Exercised

4 January в 18:05

Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study

4 January в 18:05

Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study

18 April 2023 в 02:05

Stocks to Watch: Avenue Therapeutics, Digital Brands

18 April 2023 в 02:05

Stocks to Watch: Avenue Therapeutics, Digital Brands

17 April 2023 в 23:25

Avenue Therapeutics Shares Jump 30% on FDA Meeting Minutes

17 April 2023 в 23:25

Avenue Therapeutics Shares Jump 30% on FDA Meeting Minutes

9 March 2023 в 03:05

Stocks to Watch: Avenue Therapeutics, MongoDB, Silvergate Capital, Neoleukin Therapeutics

9 March 2023 в 03:05

Stocks to Watch: Avenue Therapeutics, MongoDB, Silvergate Capital, Neoleukin Therapeutics

9 March 2023 в 00:15

Avenue Therapeutics Shares Jump 33% on Upcoming FDA Meeting on Opioid Stacking Study Risks

9 March 2023 в 00:11

Avenue Therapeutics Shares Jump 33% on Upcoming FDA Meeting on Opioid Stacking Study Risks

2 March 2023 в 18:15

Avenue Therapeutics Shares Rise 7% After Licensing Agreement for AJ201

2 March 2023 в 18:15

Avenue Therapeutics Shares Rise 7% After Licensing Agreement for AJ201

14 October 2022 в 21:07

Avenue Therapeutics Shares Jump 40% Following Stock Repurchase Move

14 October 2022 в 21:07

Avenue Therapeutics Shares Jump 40% Following Stock Repurchase Move

7 October 2022 в 14:01

Avenue Therapeutics Shares Slide Premarket After Offering Priced >ATXI

7 October 2022 в 14:01

Avenue Therapeutics Shares Slide Premarket After Offering Priced >ATXI

6 October 2022 в 19:30

Avenue Therapeutics Shares Continue Drop, Down 17% After Wednesday Loss

6 October 2022 в 19:30

Avenue Therapeutics Shares Continue Drop, Down 17% After Wednesday Loss

About company Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Address:
1140 Avenue of the America, New York, NY, United States, 10036
Company name: Avenue Therapeutics
Issuer ticker: ATXI
ISIN: US05360L2051
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2017-06-27
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.avenuetx.com

On which stock exchange are Avenue Therapeutics (ATXI) stocks traded?

Avenue Therapeutics (ATXI) stocks are traded on NASDAQ.

What is the ticker of Avenue Therapeutics stocks (ATXI)?

The stock ticker of Avenue Therapeutics’s stocks or in other words, the code is ATXI. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Avenue Therapeutics (ATXI) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Avenue Therapeutics (ATXI) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Avenue Therapeutics (ATXI) stocks traded?

Avenue Therapeutics (ATXI) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Avenue Therapeutics (ATXI) stocks today?

The current price of Avenue Therapeutics stocks on 12.05.2024 is 4 dollars. per share.

What is the dynamics of Avenue Therapeutics (ATXI) stocks from the beginning of the year?

Avenue Therapeutics (ATXI) quotes have increased by 2400% from the beginning of the year up to 4 dollars. per 1 stocks.

How much did Avenue Therapeutics (ATXI) stocks increase in мае 2024?

This month Avenue Therapeutics (ATXI) quotes have increased by -15.97% to 4 dollars. per share.

How much are Avenue Therapeutics (ATXI) stocks worth?

Today, on October, 12.05.2024 Avenue Therapeutics’s (ATXI) stocks cost 4 dollars..

What is the market capitalization of Avenue Therapeutics (ATXI)?

Capitalization is the market value of Avenue Therapeutics (ATXI) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 12.05.2024, the market capitalization of Avenue Therapeutics (ATXI) is estimated at about 102390488 dollars.